According to Next Move Strategy Consulting, the global biologics contract development market is poised for significant expansion, with a projected to USD 13.84 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 8.8% by 2030. The market’s trajectory is driven by the rising incidence of chronic diseases such as cancer, autoimmune disorders, and diabetes, along with the growing demand for advanced biologic therapies and the expanding exosome manufacturing platforms.
Biologics Contract Development: An Industry Overview
Biologics are medicines derived from living organisms, representing some of the most advanced treatments in modern healthcare. The biologics contract development market, also referred to as the biologics manufacturing market, involves outsourcing specialized services to pharmaceutical and biotech companies that need expert assistance in developing biologics. These services encompass a range of critical processes, including cell line development, process development, analytical and bioanalytical methods, formulation, and regulatory support. These services enable companies to navigate the highly regulated and complex development pathways from discovery through clinical trials to commercialization.
As pharmaceutical companies face the growing challenge of developing biologics for increasingly complex diseases, the demand for specialized expertise and infrastructure in biologics manufacturing is surging. This has led to an accelerated need for contract development organizations (CDOs) that provide these essential services.
Key Market Drivers
The demand for biologic therapies is being propelled by several key factors, including the rising prevalence of chronic diseases, the aging global population, and the increasing interest in cutting-edge biotechnologies like exosome production.
- Rising Incidence of Chronic Diseases
The world is witnessing an alarming increase in chronic diseases such as cancer, autoimmune disorders, diabetes, and cardiovascular diseases. According to the American Cancer Society, nearly 20 million cancer cases were diagnosed in 2022, with projections estimating that cancer cases will reach 35 million by 2050. Biologics are becoming a cornerstone in the treatment of these conditions due to their highly targeted and effective nature. The demand for biologics as the treatment of choice is expected to increase as these chronic diseases become more widespread. - Advancements in Exosome Manufacturing
Exosomes, small vesicles secreted by cells, have garnered attention in the biopharmaceutical industry for their potential therapeutic applications, including regenerative medicine, drug delivery, and cancer therapy. The increasing focus on exosome-based therapies has led pharmaceutical and biotech firms to partner with contract development organizations (CDOs) that specialize in the production and manufacturing of exosome products. Notably, in February 2024, EXO Biologics SA launched its ExoXpert program, a new CDO specializing in exosome manufacturing, marking a significant step toward meeting the industry’s demand for exosome-based products. - Growing Aging Population
The global aging population is another significant factor contributing to the growth of the biologics contract development market. As the number of people aged 60 and above is expected to reach 1.4 billion by 2030, with a projected doubling by 2050, the need for biologics to address age-related diseases like arthritis is increasing. Biologic therapies are crucial in improving the quality of life for elderly patients and managing age-related health conditions, further driving market demand.
Challenges to Market Growth
Despite the promising growth prospects, the Biologics Contract Development Market faces challenges. One of the major obstacles is the high cost of biologics development. Biologic drug development involves complex manufacturing processes, extended pre-clinical trials, and large-scale clinical trials, which contribute to substantial costs. These high costs can limit the ability of many pharmaceutical and biotech companies to invest in biologics development and may lead them to rely on outsourcing to contract development organizations (CDOs).
See What You’re Missing – Download a FREE Sample Now!
However, the adoption of innovative manufacturing technologies, such as single-use bioreactors and other disposable equipment, is expected to alleviate some of these challenges. These technologies can reduce operational costs by minimizing cleaning time, decreasing the risk of cross-contamination, and offering greater flexibility, ultimately improving efficiency and driving market growth.
Geographical Insights
The North American market holds a dominant share in the biologics contract development space, and this trend is expected to continue throughout the forecast period. The region benefits from the increasing number of spinal disorders and the high demand for biologic therapies to treat conditions like degenerative disc disease and spinal stenosis. The U.S. is particularly notable for its robust healthcare infrastructure and its high level of investment in biologics research and development.
Click Here for Your FREE Sample!
In October 2023, Tanvex BioPharma USA Inc. launched Tanvex CDMO, a contract development and manufacturing organization that offers a range of biologic drug development services. This move underscores the growth in demand for biologics manufacturing services and the increasing importance of outsourcing biologics development to CDOs.
On the other hand, the Asia-Pacific region is expected to witness steady growth in the biologics contract development market. This is due to the increasing demand for innovative therapies, such as cancer immunotherapies, and the growing need for biologic drugs in the pharmaceutical industry. India, for example, is expected to become a key player, with the Indian pharmaceutical industry projected to reach USD 130 billion by 2030. In November 2023, Aragen Life Sciences further solidified its position by constructing a biologics manufacturing facility in India, investing USD 30 million to support the demand for biopharmaceuticals.
Competitive Landscape
The biologics contract development market is highly competitive, with major players employing strategies such as partnerships, collaborations, and expansions to maintain their market positions. Key players in the market include AGC Biologics, Boehringer Ingelheim, Catalent, WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung Biologics, and others.
For example, in June 2023, AGC Biologics introduced the AGCellerate program, aimed at providing biopharmaceutical developers with IND-ready GMP material for biologic drugs. This program focuses on monoclonal antibodies, lentiviral vectors, and other modalities, showcasing AGC’s commitment to supporting biopharmaceutical companies at every stage of biologic development.
Additionally, in December 2023, WuXi Biologics opened a Biosafety Testing Center in Shanghai, which further expands its global footprint and supports early-phase biologic and vaccine development.
Conclusion
The biologics contract development market is positioned for substantial growth in the coming years, driven by increasing demand for biologic therapies, advancements in biotechnologies such as exosome production, and the expanding aging population. Despite challenges related to the high cost of biologics development, technological advancements and the strategic expansion of contract development organizations (CDOs) offer opportunities for sustained growth.
